Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Sera Prognostics (NASDAQ:SERA) issued its quarterly earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.03), FiscalAI reports. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%.

Here are the key takeaways from Sera Prognostics’ conference call:

• Positive Sentiment: Illinois enacted Medicaid coverage legislation for prescribed proteomic tests and related care management for spontaneous preterm-birth risk, potentially providing access to approximately 50,000 eligible births annually. Sera has begun contracting, credentialing, provider education, and workflow integration, though meaningful utilization is expected to ramp gradually.
• Positive Sentiment: Payer engagement exceeded the company’s 2026 goal, reaching more than 20 opportunities across over 20 states, while Sera launched its fourth commercial partnership and remains on track for five to seven programs. Management expects the pipeline to contribute more meaningfully as opportunities move through implementation and contracting, typically a six- to nine-month process.
• Positive Sentiment: New PRIME data in first-time mothers showed a 22% reduction in NICU admissions and a 30% reduction in severe composite neonatal morbidity, with one NICU admission prevented for every 28 patients screened and treated. The findings and upcoming SMFM presentations are intended to support broader clinical adoption and future guideline inclusion.
• Negative Sentiment: Revenue remained very modest at $30,000, despite month-to-month increases in testing volume, while the net loss widened to $9.1 million from $8.0 million year over year. Sera ended the quarter with $80.3 million in cash and expects it to fund operations through 2029, but near-term commercial conversion remains limited.
• Negative Sentiment: Sera moved its expected European CE-marking submission to the fourth quarter after deciding to conduct additional ELISA assay performance testing to reduce execution risk. Management remains confident in the regulatory plan, but the timing shift delays a potential European commercialization milestone.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA opened at $2.02 on Thursday. The stock has a market capitalization of $79.10 million, a price-to-earnings ratio of -3.11 and a beta of 0.96. Sera Prognostics has a 1-year low of $1.56 and a 1-year high of $3.95. The company’s fifty day moving average is $2.00 and its two-hundred day moving average is $2.12.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Craig Hallum initiated coverage on Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings lowered Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 20,755 shares of Sera Prognostics stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total value of $43,170.40. Following the completion of the transaction, the chief executive officer directly owned 871,999 shares of the company’s stock, valued at approximately $1,813,757.92. The trade was a 2.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 27,755 shares of company stock valued at $57,840. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Large investors have recently bought and sold shares of the business. Lido Advisors LLC bought a new position in shares of Sera Prognostics during the third quarter valued at approximately $68,000. Cetera Investment Advisers bought a new stake in shares of Sera Prognostics in the 4th quarter worth approximately $74,000. Qube Research & Technologies Ltd bought a new stake in shares of Sera Prognostics in the 2nd quarter worth approximately $92,000. Two Sigma Investments LP acquired a new position in Sera Prognostics during the 3rd quarter valued at approximately $97,000. Finally, Barclays PLC grew its stake in Sera Prognostics by 267.4% during the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after buying an additional 26,726 shares during the last quarter. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.